Lipoprotein (a) measurements for clinical application
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The high degree of size heterogeneity of apo(a), the distinct protein component of lipoprotein (a) [Lp(a)], renders the development and selection of specific antibodies directed to apo(a) more difficult and poses significant challenges to the development of immunoassays to measure its concentration in plasma or serum samples. Apo(a) is extremely variable in size not only between but also within individuals because of the presence of two different, genetically determined apo(a) isoform sizes. Therefore, the antigenic determinants per particle available to interact with the antibodies will vary in the samples and the calibrators, thus contributing to apo(a) size-dependent inaccuracy of different methods. The lack of rigorous validation of the immunoassays and common means of expressing Lp(a) concentrations hinder the harmonization of results obtained by different studies and contribute to the lack of common cut points for identification of individuals at risk for coronary artery disease or for interventions aimed at reducing Lp(a) levels. The aim of our review is to present and critically evaluate the issues surrounding the measurements of Lp(a), their impact on the clinical interpretation of the data, and the obstacles we need to overcome to achieve the standardization of Lp(a) measurements.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is important to note that direct LDL-C measurements also have limitations, including systematic bias and inaccuracy in patients with dyslipidaemia, especially for high TG levels [88-90].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [90]
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,296
Sharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 944
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Lipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 558
Cited by
Items 101–200 of 337
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia
Olmastroni, E., Gazzotti, M., Averna, M. R., Arca, M., Tarugi, P., Calandra, S., Bertolini, S., Catapano, A. L., Casula, M., Arca, M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029223 · Cited by 31
“24”
Yeang, C., Clopton, P., & Tsimikas, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.012 · Cited by 29
Clouet-Foraison, N., Marcovina, S. M., Guerra, E., Aarsand, A. K., Coşkun, A., Díaz–Garzón, J., Fernández–Calle, P., Sandberg, S., Ceriotti, F., & Carobene, A. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa054 · Cited by 27
Self-citationQuantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)
Rosenson, R. S., López, J. A. G., Monsalvo, M. L., Wu, Y., Wang, H., & Marcovina, S. M. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07407-y · Cited by 29
Self-citationThe role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
Vavuranakis, M., Jones, S. R., Cardoso, R. N., Gerstenblith, G., & Leucker, T. M. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.09.016 · Cited by 29
Bhatia, H. S., Rikhi, R. R., Allen, T. S., Yeang, C., Guan, W., Garg, P. K., Tsai, M. Y., Criqui, M. H., Shapiro, M. D., & Tsimikas, S. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117217 · Cited by 32
Singh, S., Baars, D. P., Aggarwal, K., Desai, R., Singh, D., & Pinto‐Sietsma, S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102439 · Cited by 32
Cohort profile: role of lipoproteins in cardiovascular disease—the LipidCardio study
König, M., Joshi, S., Leistner, D. M., Landmesser, U., Sinning, D., Steinhagen‐Thiessen, E., & Demuth, I. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030097 · Cited by 24
“Lp(a) is given in nmol/L, correctly reflecting the number of Lp(a) particles.(14) A range of other parameters were taken over from the hospital information system, provided that they were ordered as part of the clinical routine.”
BackgroundRecent Updates of Lipoprotein(a) and Cardiovascular Disease
Liu, T., Yoon, W.-S., & Lee, S. R. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.1.36 · Cited by 26
Liu, H., Cao, Y., Jin, J., Hua, Q., Li, Y., Guo, Y., Zhu, C., Wu, N., Dong, Q., & Li, J. (2021) · Hypertension Research · doi:10.1038/s41440-021-00668-4 · Cited by 27
Zhang, H., Zhang, Y., Tian, T., Wang, T., Chen, J., Yuan, J., Qian, J., Hu, F., Dou, K., Qiao, S., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.094 · Cited by 28
Cao, J., Steffen, B. T., Guan, W., Budoff, M. J., Michos, E. D., Kizer, J. R., Post, W. S., & Tsai, M. Y. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.270751 · Cited by 27
“The Lp(a)-M method used in the current study is an immunoassay that measures concentrations of Lp(a) expressed in milligrams per deciliter rather than nanomoles per liter—the latter being recommended by the IFCC Lp(a) standardization program (12).”
MethodLipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy
Iannuzzo, G., Tripaldella, M., Mallardo, V., Morgillo, M., Vitelli, N., Iannuzzi, A., Aliberti, E., Giallauria, F., Tramontano, A. L., Carluccio, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070838 · Cited by 35
“Lp(a) also presents significantly different distribution in various populations, with the lowest levels in Caucasian and the highest in Africans, but there is not an established race specific clinical cut-off point.”
BackgroundLittmann, K., Hagström, E., Häbel, H., Bottai, M., Eriksson, M., Parini, P., & Brinck, J. W. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab016 · Cited by 24
Marco-Benedí, V., Cenarro, A., Laclaustra, M., Larrea, A., Jarauta, E., Lamíquiz-Moneo, I., Calmarza, P., Bea, A. M., Plana, N., Pintó, X., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.009 · Cited by 25
Hober, A., Edfors, F., Ryaboshapkina, M., Malmqvist, J., Rosengren, L., Percy, A. J., Lind, L., Forsström, B., Uhlén, M., Oscarsson, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001765 · Cited by 26
“Apo(a) is highly variable in structure and size (63).”
Clarke, R., Wright, N., Lin, K., Yu, C., Walters, R. G., Lv, J., Hill, M., Kartsonaki, C., Millwood, I. Y., Bennett, D., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072086 · Cited by 33
“29 Comparison of Lp(a) levels obtained by both assay types enabled an assessment of the validity of the polyclonal Lp(a) assay to measure Lp(a) in East Asian populations.”
Self-citationFlorentin, M., Elisaf, M., Rizos, C. V., Nikolaou, V., Bilianou, E., Pitsavos, C. E., & Liberopoulos, E. N. (2016) · Lipids · doi:10.1007/s11745-016-4216-z · Cited by 23
“Lp(a) is synthesized by the liver and contains a cholesterol rich LDL particle and apolipoprotein (apo) (a); the latter is attached to apoB-100 via a disulfide bond [2].”
BackgroundLipoprotein(a): a genetically determined risk factor for Cardiovascular disease
Marcovina, S. M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2229915 · Cited by 28
“…Evaluation of the factors affecting Lp(a) measurements, the impact of the inaccuracy of methods on the clinical interpretation of Lp(a) data, and the use of the monoclonal antibody-based ELISA to standardize Lp(a) analytical methods have been extensively reviewed [76] and will not be repeated here.”
BackgroundMethodInfluentialSelf-citationRethinking cardiovascular risk: The emerging role of lipoprotein(a) screening
Clair, V., Zirille, F. M., & Gill, E. A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100945 · Cited by 26
“Although WHO/IFCC reference materials are no longer available, this validation method supports the use of these assays until new reference materials become available [15].”
InfluentialEmerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels
Eraikhuemen, N., Lazaridis, D., & Dutton, M. T. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00437-7 · Cited by 21
“Advances in our knowledge of non-LDL-C physiology and improved assay techniques have shed more light on the role of Lp(a) in the pathogenesis of atherosclerotic vascular diseases [3].”
BackgroundLipoprotein (a) and diabetes mellitus: causes and consequences
Ward, N. C., Vickneswaran, S., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000597 · Cited by 25
Welsh, P. I., Welsh, C. E., Celis-Morales, C. A., Brown, R., Ferguson, L. D., Gray, S. R., Mark, P. B., Lewsey, J., Lyall, D. M., Gill, J. M. R., et al. (2020) · European Heart Journal · doi:10.1093/ehjci/ehaa946.2833 · Cited by 21
Solnica, B., Sygitowicz, G., Sitkiewicz, D., Jozwiak, J. J., Kasperczyk, S., Broncel, M., Wolska, A. T., Odrowąż‐Sypniewska, G., & Banach, M. (2024) · Archives of Medical Science · doi:10.5114/aoms/186191 · Cited by 43
“…to the rate of its synthesis mainly in the liver and the serum/plasma concentration – particles of a lower mass (lower number of KIV-2 repeats) are present in higher concentrations, while particles of a higher mass (high number of KIV-2 repeats) are present in lower concentrations [10, 72].”
BackgroundLipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician
Jha, M., Raber, I., & Gelfand, E. V. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.034 · Cited by 22
Vuorio, A. F., Watts, G. F., & Kovanen, P. T. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx546 · Cited by 24
The Inherited Hypercholesterolemias
Loh, W. J., & Watts, G. F. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.006 · Cited by 24
The ins and outs of lipoprotein(a) assay methods
Heydari, M., Rezayi, M., Ruscica, M., Jamialahmadi, T., Johnston, T. P., & Sahebkar, A. (2024) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/176653 · Cited by 23
“This could lead Lp(a) levels to be overestimated or underestimated in clinical samples containing large or small isoforms, respectively [67].”
BackgroundLp(a): Addressing a Target for Cardiovascular Disease Prevention
Vasquez, N., & Joshi, P. H. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1182-0 · Cited by 20
Hedegaard, B. S., Nordestgaard, B. G., Kanstrup, H., Thomsen, K. K., Bech, J. W., Bang, L. E., Henriksen, F. L., Andersen, L. J., Gohr, T., Larsen, L., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad625 · Cited by 23
Wyness, S. P., & Genzen, J. R. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00218 · Cited by 20
“Many vendors have participated in the harmonization activities described above, as well as initiatives from the Northwest Lipid Metabolism and Diabetes Research Laboratories (NLMDRL) [15,22,23].”
BackgroundInfluentialBerman, A. N., Biery, D. W., Ginder, C. R., Hulme, O. L., Marcusa, D. P., Leiva, O., Wu, W. Y., Singh, A., Divakaran, S., Hainer, J. M., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23456 · Cited by 19
“The first methodology was the standard immunochemical-based assay with reference ranges <30 mg/dL or < 75 nmol/L.(10,28,29) The second assay type was a clinically validated electrophoretic assay measuring the cholesterol content of Lp(a) particles with a reference range < 3 mg/dL.”
MethodWong, N. D., Zhao, Y., Sung, J., & Browne, A. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.075 · Cited by 20
“The study design of the trial has been previously published (9).”
BackgroundYing, Q., Chan, D. C., Pang, J., Marcovina, S. M., Barrett, P. H. R., & Watts, G. F. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13457 · Cited by 21
Self-citationLaw, H. G., Khan, M. A., Zhang, W., Bang, H., Rood, J. C., Most, M. M., Lefevre, M., Berglund, L., & Enkhmaa, B. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100420 · Cited by 19
“Furthermore, calibrators of nephelometric assays are usually selected to have high Lp(a) levels (33) with a potential consequence of overestimating Lp(a) values for cohorts with low Lp(a) levels (e.”
BackgroundSerum lipoprotein (a) predicts acute coronary syndromes in patients with severe carotid stenosis
Rigamonti, F., Carbone, F., Montecucco, F., Bonaventura, A., Liberale, L., Burger, F., Roth, A., Bertolotto, M. B., Spinella, G., Pane, B., et al. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12888 · Cited by 18
“Also due to different methods of measurement, Lp (a) cut-off values are quite heterogeneous in current publications.(23) For instance, Lp (a) levels ranging from 10 to 77 mg/dL were indicated to predict cardiovascular events.”
MethodElevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity
Tavori, H., Fenton, A. M., Plubell, D. L., Rosário, S., Yerkes, E., Gasik, R. E., Miles, J., Bergstrom, P., Minnier, J., Fazio, S., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02708 · Cited by 18
Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)
Chakraborty, A., Chan, D. C., Ellis, K. L., Pang, J., Barnett, W., Woodward, A. M., Vorster, M., Norman, R., Moses, E. K., & Watts, G. F. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100343 · Cited by 19
“Our use of an apo(a) isoform sensitive immunoassay to quantitate Lp(a) mass, with potential bias from the effects of larger and smaller isoform sizes [23], is another limitation.”
MethodMarcovina, S. M., & Shapiro, M. D. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.053 · Cited by 18
Self-citationSleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
Коростовцева, Л. С., Alieva, A. S., Rotar, O. P., Викторович, Б. М., Boyarinova, M. A., Sviryaev, Y. V., Конради, А. О., & Shlyakhto, E. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134680 · Cited by 18
“At the same time, recent studies have demonstrated that, while increased Lp(a) levels are associated with enhanced atherogenesis, proinflammatory and prothrombotic states [16], a greater risk of cardiovascular events, and poorer prognosis [2,15,17,18], the decreased serum concentrations of Lp(a) are related to the ins…”
BackgroundLipoprotein(a) in clinical practice: A guide for the clinician
Krittanawong, C., Maitra, N. S., Sherbini, A. E., Shah, N. R., Lavie, C. J., Shapiro, M. D., & Virani, S. S. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.07.006 · Cited by 17
Current and future role of lipoprotein(a) in preventive cardiology
Berman, A. N., & Blankstein, R. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000661 · Cited by 16
“ment techniques utilize a variety of calibrators and work to create so-called isoform ‘insensitive’ assays [8,13,23,24].”
Page, M. M., Ellis, K. L., Pang, J., Chan, D. C., Hooper, A. J., Bell, D. A., Burnett, J. R., & Watts, G. F. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.07.029 · Cited by 16
PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
Mefford, M. T., Marcovina, S. M., Bittner, V., Cushman, M., Brown, T. M., Farkouh, M. E., Tsimikas, S., Monda, K. L., López, J. A. G., Muntner, P., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p119000173 · Cited by 17
“Lp(a) concentrations are higher for black adults, and a larger proportion of black compared with white adults have medium-sized apo(a) isoforms (37, 38).”
BackgroundSelf-citationSwearingen, C., Sloan, J. H., Rhodes, G. M., Siegel, R. W., Bivi, N., Qian, Y., Konrad, R. J., Boffa, M. B., Koschinsky, M. L., Krege, J. H., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100723 · Cited by 19
“A common approach to partially overcome this quantitative issue is to apply multi-point calibrators with a range of isoform sizes and concentrations (9, 11).”
Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
Oliveira, C., Fournier, C., Descamps, V., Morel, V., Scipione, C. A., Romagnuolo, R., Koschinsky, M. L., Boullier, A., Marcelo, P., Domon, J.-M., et al. (2017) · Hepatology · doi:10.1002/hep.29096 · Cited by 16
“An inverse correlation between the size of apo(a) isoforms and the serum levels of Lp(a) (ranging from< 1 to> 100mg/dL) has been described,((10)) and elevated plasma concentrations of Lp(a) have been identified as a risk factor for vascular diseases such as peripheral arterial disease, ischemic stroke, and coronary he…”
BackgroundParthymos, I., Kostapanos, M. S., Mikhailidis, D. P., & Florentin, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab052 · Cited by 15
Mukherjee, D., & Nissen, S. E. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611267835231210054909 · Cited by 16
Akyol, Ö., Yang, C.-Y., Woodside, D. G., Chiang, H., Chen, C., & Gotto, A. M. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01209-3 · Cited by 15
“Patients with elevated levels of oxPL-apoB100 or Lp(a) showed enhanced uptake of 18 F-NaF [58], indicating increased calcific activity, and had poorer clinical outcomes than those with normal levels [59].”
BackgroundRazavi, A. C., Bhatia, H. S., Blumenthal, R. S., Shapiro, M. D., & Mehta, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16469 · Cited by 19
“33 The primary challenge stems from the variability in the number of KIV-2 repeats in apo(a).”
Boffa, M. B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0622-1 · Cited by 15
Tuteja, S., Wang, L., Dunbar, R. L., Chen, J., DerOhannessian, S. L., Marcovina, S. M., Elam, M. B., Lader, E. W., & Rader, D. J. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000289 · Cited by 15
Self-citationJCL roundtable—Lipoprotein(a): The emerging risk factor
Marcovina, S. M., Moriarty, P. M., Koschinsky, M. L., & Guyton, J. R. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.11.003 · Cited by 14
Self-citationLipoprotein(a): Role in atherosclerosis and new treatment options
Tomić-Naglić, D., Manojlovic, M. S., Pejaković, S., Stepanović, K., & Prodanović, J. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.8992 · Cited by 18
Weiss, M. C., Berger, J. S., Gianos, E., Fisher, E. A. A., Schwartzbard, A. Z., Underberg, J. A., & WEINTRAUB, H. S. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.005 · Cited by 14
Zheng, W., Chilazi, M. J., Park, J., Sathiyakumar, V., Donato, L. J., Meeusen, J. W., Lazo, M., Guallar, E., Kulkarni, K. R., Jaffe, A. S., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023136 · Cited by 15
Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population
Hussain, Z. B., Iqbal, J., Liu, H., & Zhou, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123586 · Cited by 16
Lipoprotein(a): cardiovascular risk and emerging therapies
Fujino, M., & Nicholls, S. J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2197593 · Cited by 15
“It should be noted that renal insufficiency or low estrogen levels may cause a slight increase of Lp(a), and surgery or inflammation may also cause a transient increase of Lp(a) [21–23], although fasting is not required for Lp(a) measurement [24].”
BackgroundShapiro, M. D., Haddad, T. M., WEINTRAUB, H. S., Baum, S. J., Abdul-Nour, K., Sarwat, S., Paluy, V., Boatwright, W., Browne, A., Ayaz, I., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.007 · Cited by 17
Lipoprotein(a): the common, likely causal, yet elusive risk factor for cardiovascular disease
Kamstrup, P. R. (2017) · Journal of Lipid Research · doi:10.1194/jlr.c079111 · Cited by 14
“studies used long-term frozen samples and questionable assays, underscoring the importance of using appropriate sample material and validated Lp(a) assays to yield reliable results (3).”
BackgroundPage, M. M., & Watts, G. F. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000842 · Cited by 14
“Several issues have impeded the accurate measurement of Lp(a) in the clinical setting for several decades [52].”
BackgroundLipoprotein (a): A new target for pharmacological research and an option for treatment
Pirillo, A., & Catapano, A. L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.021 · Cited by 16
Wang, Z., Xiao, S., & Liu, N. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117220 · Cited by 16
Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease
Bellomo, T. R., Liu, Y., Gilliland, T., Miksenas, H., Haidermota, S., Wong, M. Y., Hu, X., Cristino, J. R., Browne, A., Plutzky, J., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100585 · Cited by 14
“No statistically or clinically significant bias was observed between Lp(a) measurements obtained by the LPA4/LPA-KIV9 ELISA and those obtained by the gold-standard University of Washington assay, and therefore, the methods were previously determined to be equivalent (35).”
MethodLipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience
Pino, B. D., Gorini, F., Gaggini, M., Landi, P., Pingitore, A., & Vassalle, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030764 · Cited by 11
Poudel, B., Rosenson, R. S., Kent, S. T., Bittner, V., Gutiérrez, O. M., Anderson, A. H., Woodward, M., Jackson, E. A., Monda, K. L., Bajaj, A., et al. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100648 · Cited by 13
“Lp(a) molar concentration may also be a better marker of the risk for ASCVD events than apolipoprotein(a) size or Lp(a) mass concentration.(28,38) In a prior study conducted in Iceland, higher Lp(a) molar concentration was associated with a lower apolipoprotein(a) size and an increased risk for CHD events.”
BackgroundGonen, A., Yang, X., Yeang, C., Alekseeva, E. A., Koschinsky, M. L., Witztum, J. L., Boffa, M. B., & Tsimikas, S. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000830 · Cited by 13
Nicholls, S. J., & Bubb, K. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01528-w · Cited by 13
Anchouche, K., Baass, A. W., & Thanassoulis, G. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110929 · Cited by 13
Wang, Z., Xiao, S., & Liu, N. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117226 · Cited by 11
Recent AHA/ACC guidelines on cholesterol management expands the role of the clinical laboratory
Cao, J., & Devaraj, S. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.04.002 · Cited by 12
Lan, N. S. R., Chan, D. C., Pang, J., Fegan, P. G., Yeap, B. B., Rankin, J. M., Schultz, C. J., Watts, G. F., & Bell, D. A. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.932 · Cited by 11
Prevalence and status of Lipoprotein (a) among Lebanese school children
Gannagé‐Yared, M., Lahoud, C., Younès, N., Chédid, R., & Sleilaty, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-77689-5 · Cited by 14
Ying, Q., Ronca, A., Chan, D. C., Pang, J., Favari, E., & Watts, G. F. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13766 · Cited by 9
Tsushima, T., Tsushima, Y., Sullivan, C., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.011 · Cited by 10
Will you, nill you, I will treat you: the taming of lipoprotein(a)
von Eckardstein, A. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx232 · Cited by 12
A potentially underestimated predictor of coronary artery disease risk: The ApoB/ApoA1 ratio
Li, B., Zhao, X., Ding, Y., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32084 · Cited by 11
“Lp(a) is a complex consisting of Apo(a) covalently bound to LDL [35]; Apo(a) contains a variable number of Kringle-IV type 2 repeats associated with variability in measured levels of Lp(a); high levels of Lp(a) are associated with CAD risk [36]; and previous MR analyses have shown a causal…”
BackgroundDelgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.07.008 · Cited by 24
Hu, X., Wang, C., Feng, D., Li, Z., Chen, Y., Niu, G., Zhou, Z., Zhang, H., Ye, Y., Wang, M., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.001 · Cited by 9
Nordestgaard, A. G., Chasman, D. I., Moorthy, M. V., Kraaijenhof, J. M., Cook, N. R., Lee, I.-M. M., Buring, J. E., & Ridker, P. M. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5043 · Cited by 11
No small task: therapeutic targeting of Lp(a) for cardiovascular disease
Feinberg, M. W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31329-0 · Cited by 10
Circulating Biomarkers for Laboratory Diagnostics of Atherosclerosis—Literature Review
Bordeianu, G., Mitu, I., Stănescu, R., Ciobanu, C. P., Petrescu-Dănilă, E., Marculescu, A. D., & Dimitriu, D. C. (2022) · Diagnostics · doi:10.3390/diagnostics12123141 · Cited by 12
“The method based on latex-enhanced turbidimetry (kit assay by Denka Seiken, Japan) is considered very reliable [36].”
MethodLipoprotein(a): a Case for Universal Screening in Youth
Alankar, A., Brar, P. C., & Kohn, B. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01120-3 · Cited by 10
Diederiks, N. M., Ruhaak, L. R., Romijn, F. P. H. T. M., Pieterse, M., Smit, N. P. M., & Cobbaert, C. M. (2024) · Clinical Proteomics · doi:10.1186/s12014-023-09446-5 · Cited by 9
“Measurements in Cobbaert et al. [23] were performed using a former state-of-the-art Lp(a) test, not yet standardized to the former Reference Measurement System (RMS) [23, 24].”
MethodAll we need to know about lipoprotein(a)
Bess, C., Mehta, A., & Joshi, P. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.05.007 · Cited by 17
Zhang, Y., Ren, X., Zhou, Z., Wang, D. W., Rao, X., Ding, H., & Wu, J. (2024) · The Analyst · doi:10.1039/d4an00221k · Cited by 8
Abdalla, H., Mahmoud, A., Khedr, A. E., Farina, J., Scalia, I. G., Abbas, M. T., Awad, K., Ali, N. B., Bismee, N. N., Esfahani, S. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011029 · Cited by 10
“This lipid core is encircled by apolipoprotein B100 (apoB), a hydrophilic molecule also found in LDL that ensures structural stability [39].”
BackgroundResultNikoli, A., Orfanidou, M., Goulas, A., Goulis, D. G., & Pοlyzos, S. A. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16768 · Cited by 10
Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
Pfeferman, M. B., Rashedi, S., Lip, G. Y. H., Weber, C., O’Donoghue, M. L., Nissen, S. E., Nicholls, S. J., Natarajan, P., Plutzky, J., Libby, P., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2674-5114 · Cited by 14
“41 The unique functional and metabolic features of Lp(a) are mainly attributed to the presence of apo(a), 42 as well as the large amount of oxidized phospholipids (OxPLs) carried by the particle 43 ( ► Fig.”
Lipoprotein(a) and Familial Hypercholesterolemia: A Short Review Including the Laboratory Viewpoint
Hamasaki, M., & Kotani, K. (2020) · Cardiology Research · doi:10.14740/cr1145 · Cited by 11
“The standard assay, which is the method of the Northwest Lipid Metabolism and Diabetes Research Laboratories, measures the molar-based value (expressed in nmol/L) [15].”
BackgroundMethodInfluentialExploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk
Corral, P., Matías, A., Cobo, A. L., Sergio, G., & Federico, R. N. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01543-5 · Cited by 9
“This variability, particularly in type 2 repeats, contributes to the high size variability in apo(a), serving as a key factor in the heterogeneity in the size of Lp(a) [8].”
Lipoprotein(a) particle number assay without error from apolipoprotein(a) size isoforms
Contois, J. H., Nguyen, R.-A., & Albert, A. L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.02.030 · Cited by 8
Selected biomarkers of atherosclerosis - clinical aspects
Surma, S., Czober, T., Lepich, T., Sierka, O., & Bajor, G. (2020) · Acta Angiologica · doi:10.5603/aa.2020.0005 · Cited by 15
“Lipoprotein (a) — Lp (a) Lipoprotein (a) is a modified LDL lipoprotein by attaching a specific apolipoprotein (a) to apoB100 [43].”
BackgroundLipoprotein(a) in the Korean Pediatric Population Visiting Local Clinics and Hospitals
Choi, R., Lee, S. G., & Lee, E. H. (2022) · Nutrients · doi:10.3390/nu14142820 · Cited by 8
Ansari, S., Neely, R. D. G., Payne, J., & Cegla, J. (2023) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632231210682 · Cited by 7
Schettler, V. J. J., Ringel, J., Jacob, S., Julius, U., Klingel, R., Heigl, F., Roeseler, E., & Grützmacher, P. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.005 · Cited by 7
Quantifying the contribution of lipoprotein(a) to all apoB containing particles
Chilazi, M. J., Zheng, W., Park, J., Marvel, F. A., Khoury, S. R., Jones, S. R., & Martin, S. S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.02.004 · Cited by 8
Lp(a) Levels in Relatives of Patients with Acute Coronary Syndrome and Elevated Lp(a): HER(a) Study
Fernández-Olmo, M. R., Bailén, M. C., Quesada, M. M., Mansilla, C. R., Toro, M. M., Suárez, A. L., García, M. L., Quiroga, G. A. C., Bernal, B. C., Cruces, S. O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082256 · Cited by 7
Deconinck, A., Morra, S., Glassée, N., & van de Borne, P. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2031377 · Cited by 7
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
Grützmacher, P., Öhm, B., Szymczak, S., Dorbath, C., Brzoska, M., & Kleinert, C. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0090-3 · Cited by 7
Metadata
- Authors
- Marcovina, S. M., & Albers, J. J.
- Affiliations
- University of Washington (US)
- Corresponding author
- Marcovina, Santica M.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 57
- Issue
- 4
- Pages
- 526-537
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4808779
- OpenAlex
- W2313206757
- Cited by
- 338
- References
- 49
- Citations by year
- 2026: 44 · 2025: 36 · 2024: 37 · 2023: 45 · 2022: 31 · 2021: 29 · 2020: 35 · 2019: 28 · 2018: 16 · 2017: 26 · 2016: 11
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1631 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), apolipoprotein(a), apo(a) isoforms, immunoassay standardization, antibody specificity, size heterogeneity, assay validation, measurement harmonization, coronary artery disease risk, clinical interpretation
- MeSH terms
- Apolipoproteins A, Cardiovascular Diseases, Data Interpretation, Statistical, Humans, Immunoassay, Reference Standards, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.